November 6, 2026
Have you ever finished a full meal, felt completely satisfied, and still found yourself searching the kitchen for something sweet? Maybe you were not hungry, but the thought of chocolate, chips, or your favorite snack just would not go away.
For many people, managing weight is not simply about eating smaller portions. Sometimes, the bigger challenge is dealing with persistent food cravings, emotional eating, and the constant thoughts about what to eat next.
This is why modern medical weight management looks beyond calorie intake alone. Appetite, hormones, brain chemistry, and everyday eating behaviors can all influence a person's weight loss journey.
GLP-1 medications and naltrexone are two medications that work through different pathways related to appetite and eating behavior. Understanding their individual effects helps explain why healthcare professionals consider different approaches when creating personalized weight management plans.
Let's take a closer look at how these medications work and how they fit into the bigger picture of weight management.
Hunger and food cravings are not exactly the same thing.
Hunger is the body's natural signal that it needs energy. Cravings, on the other hand, can happen even when the stomach is already full. They may be triggered by emotions, stress, habits, food smells, or the brain's reward system.
For example, someone might feel satisfied after dinner but still want ice cream because it has become part of their nightly routine. Another person might reach for snacks whenever work becomes stressful.
These experiences involve several interconnected processes in the brain.
The hypothalamus helps regulate hunger and fullness, while the brain's reward pathways influence how pleasurable or satisfying certain foods feel. This helps explain why some people continue struggling with their eating patterns even when they understand nutrition and have already tried changing their diet.
Weight management is therefore about more than willpower. Understanding what drives hunger and eating behavior can help healthcare professionals identify more appropriate treatment strategies.
GLP-1 stands for glucagon-like peptide 1, a naturally occurring hormone involved in blood sugar regulation and appetite control.
Medications such as semaglutide mimic the activity of this hormone. They act on areas of the brain involved in appetite regulation and help people feel satisfied with smaller amounts of food.
In simple terms, GLP-1 medications can help:
They also slow stomach emptying, contributing to prolonged feelings of fullness.
Clinical research on semaglutide has demonstrated improvements in appetite control, feelings of fullness, and certain food cravings among adults living with obesity.
This is one reason GLP-1 medications have become an important option in medical weight management. Rather than relying entirely on conscious efforts to eat less, these treatments influence the biological signals involved in appetite regulation.
For individuals who struggle with frequent hunger, large portions, or difficulty feeling satisfied after meals, appetite regulation can be an important part of their weight loss plan.
Unlike GLP-1 medications, naltrexone does not primarily work by increasing fullness or slowing digestion.
Naltrexone is an opioid receptor antagonist. In simple terms, it blocks certain opioid receptors in the brain that are involved in reward, pleasure, and reinforcement.
Why does this matter when it comes to eating?
Certain foods, particularly those rich in sugar and fat, can activate the brain's reward pathways. This can make eating pleasurable and encourage people to repeat the behavior, even when they are not physically hungry.
Naltrexone influences these reward related processes by blocking opioid receptors. This is one reason it is used in treatments involving certain reward driven behaviors.
Naltrexone is also prescribed for alcohol use disorder and opioid use disorder. It is not independently FDA approved as a weight loss medication.
However, it is an ingredient in Contrave, an FDA approved prescription medication for chronic weight management. Contrave combines naltrexone with bupropion.
Bupropion affects dopamine and norepinephrine activity, while naltrexone helps modify opioid related feedback in the brain's appetite and reward pathways. Together, these medications can help influence appetite and eating behavior.
This combination provides another medication option for eligible individuals seeking medical support for weight management.
GLP-1 medications and naltrexone influence different aspects of eating behavior.
Think of it this way: GLP-1 medications help regulate the body's hunger and fullness signals, while naltrexone acts on certain reward related processes in the brain.
A person using a GLP-1 medication may notice that they feel full faster, eat smaller portions, and experience less physical hunger throughout the day.
Naltrexone, particularly when combined with bupropion as in Contrave, works through pathways involved in appetite regulation and reward related eating behaviors.
These different mechanisms highlight an important part of medical weight management: not everyone experiences hunger and food cravings in the same way.
Some individuals struggle primarily with physical hunger, while others find emotional triggers and habitual eating more challenging. Many experience a combination of both.
Understanding these patterns helps healthcare professionals determine which treatment approach may be appropriate for each patient.
Imagine someone who has started a medically supervised weight loss program. They notice that they feel full faster, eat smaller portions, and no longer experience the same level of hunger throughout the day.
However, they still struggle with reaching for snacks whenever they feel stressed, bored, or emotionally overwhelmed.
This illustrates why weight management involves more than reducing appetite.
GLP-1 medications can help address physical hunger and fullness, while medications that influence reward related pathways may be considered when evaluating certain eating behaviors.
For eligible patients, healthcare professionals may also consider FDA approved options such as naltrexone combined with bupropion, depending on their medical history and weight management needs.
It is important to understand that using GLP-1 medications together with naltrexone alone is not an established weight loss treatment. These medications should not automatically be combined simply because they work through different pathways.
The appropriate approach depends on the patient's health history, current medications, treatment goals, and individual response to therapy.
A personalized weight management plan helps ensure that medication choices are made with both effectiveness and safety in mind.
Weight loss medications can offer valuable support, but choosing the right treatment requires a careful review of a person's health history.
Naltrexone requires particular attention because it blocks opioid receptors. People currently taking opioid medications, including certain prescription pain relievers, must inform their healthcare provider before considering treatment.
Starting naltrexone in someone who is physically dependent on opioids can trigger sudden and severe withdrawal symptoms. It can also interfere with the effectiveness of opioid pain medications.
Other important considerations include:
Patients should never add naltrexone to an existing GLP-1 treatment plan or adjust medication doses without consulting a qualified healthcare provider.
A medical evaluation helps determine which medications are suitable, what potential risks should be considered, and how treatment should be monitored.
Medication can be an important part of weight management, but long term progress also involves building habits that support overall health.
A sustainable weight loss plan should consider nutrition, physical activity, sleep, stress management, and consistency.
Here are a few practical ways to support your progress:
These habits complement medically supervised treatment and help create a more balanced approach to weight management.
Weight loss is not always a straightforward battle between hunger and willpower. The brain, digestive system, hormones, emotions, and everyday habits all play a role in how people eat.
GLP-1 medications help regulate appetite and fullness, while naltrexone influences opioid related reward pathways. Naltrexone is also used in combination with bupropion in an FDA approved weight management medication for eligible patients.
Understanding these different mechanisms allows healthcare professionals to look beyond the number on the scale and consider the factors that may be affecting a person's weight loss progress.
The goal is not simply to suppress hunger or eliminate every craving. It is to develop a treatment plan that supports healthier eating habits, improved metabolic health, and sustainable weight management.
At Mango Telemedicine, personalized medical guidance is an important part of the weight loss journey. Because every individual has different health needs and treatment considerations, consulting a qualified healthcare professional can help determine which approach is most appropriate.
Your weight loss journey should be about finding a plan that works with your body's needs, not fighting against it.
Billes, S. K., Sinnayah, P., & Cowley, M. A. (2014). Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss. Pharmacological Research, 84, 1–11.
Gabe, M. B. N., Breitschaft, A., Knop, F. K., Hansen, M. R., Kirkeby, K., Rathor, N., & Adrian, C. L. (2024). Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, Obesity and Metabolism, 26(10), 4480–4489.
U.S. Food and Drug Administration. (2025). Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended release tablets: Prescribing information.
Clarify the GLP-1 combination distinction
